- Email: [email protected]
Experimental comparative study of adjuvant and neoadjuvant chemotherapy, or hormonotherapy or immunotherapy applied to a hormone receptor carrying murine mammary tumor
WORKSHOP 18 NOVEL ASPECTS AND APPROACHES
IN I M M U N E M A N I P U L A T I O N
14:30 - 15:30
POSTER PRESENTATION
R o o m 1 (Naniwa Kaikan)
15:30 - 17:30
ORAL PRESENTATION
H a l l C (International House, Osaka)
Chairpersons: Anthony C. Allison (U.S.A.) Tomio Tada (Japan) * An asterisk indicates an oral presentation; the number following the asterisk is the order of the presentation.
WS18-1 -1 EXPERIMENTAL COMPARATIVE STUDY OF ADJUVANT AND NEOADJUVANT CHEMOTHERAPY, OR HORMONOTHERAPY OR IMMUNOTHERAPY APPLIED TO A HORMONE RECEPTOR CARRYING MURINE MAMMARY TUMOR. G. Math6, C. Bourut, E. Chenu, Y. Kldanl, Y. Mauvernay, A . V . $chally. ICIG, Hop. PauI-Brouase, 94804-VIIlelulf, France. MA 16/C Is a spontaneous, hormone-dependent, mouse mammary adenocarclnoma. It was Inlected s . c . on C 3 H / H e female mice on day O. Tumors were excised on day 16. Neoadluvant treatments were applied from day 1 to day 21 for hormonotherapy and Immunotherapy, and on days f , 6 end 9 for chemotherapy. Adluvant treatments were applied from day 21 to clay 42 for hormonotherapy and Immunotherapy, and on days 21, 26 end 29 for chemotherapy. Mixed (neoadluvant and edluvant) treatments combined the two patterns. Chemotherapy consisted of an oxalato-platlnum complex of trans-I-dach (I-OHP) at the dose of 6 m g / k g I . p . Hormonotherapy conalMed of D - T r p 6 - L H - R H at the dose of 1001¢g/kg I. p. . Immunotherapy consisted of zinc gluoonate, known to regulate CD8 cells at the dose of 6mg/kg per ca, and of bestafin, known to regulate CD4 cells at the dose of 8mg/kg per ca. In the condition where surgery alone did not cure any animal, adluvant or neoadluvant chemotherapy or the combination of both, induced about 30% cure at the second month, which Is a highly significant benefit I s compared to surgery alone. Adluvant hormonotherapy or neoadluvant or the combination of both, neoadtuvant and adluvant lmmunotherapy give a benefit which is not significantly different from that of chemotherapy.
WS18-2 *2 TRIAL OF A N T I C A N C E R I M M U N O - T H E R A P Y U S I N G H E M O P E R F U S I O N BY L I P O P O L Y S A C C H A R I D E I M M O B I L I Z E D FIBER K. Numa, T. Tani, Y. Endo, T. Yoshioka, M. Kodama. D e p a r t m e n t of Surgery, Shiga U n i v e r s i t y of Medical Science, Shiga Japan. L i p o p o l y s a c c h a r i d e (LPS) can be i m m o b i l i z e d to the insoluble carrier fiber (LPS-F) to utilize LPS as an a n t i c a n c e r agent without toxicity. The d e n s i t y of i m m o b i l i z e d LPS was 4 . 3 m g / g of p o l y s t y r e n e fiber. A n t i c a n c e r a c t i v i t i e s were e x a m i n e d in Vx2 tumor b e a r i n g rabbits by the t r e a t m e n t of direct h e m o p e r f u s i o n (DHP) with LPSF. Exp. I: Cancer b e a r i n g rabbits were t r e a t e d by single DHP with LPS-F 14 days after tumor inoculation. Exp. 2: A d d i n g BCG as a p r i m i n g agent. Exp. 3: U s i n g 0K-432 as a p r i m i n g agent. Exp. 4: T r e a t e d by DHP with dea cyl a t e d LPS-F (LPS was d e - a c y l a t e d by h y d r o x y l a m i n e and i m m o b i l i z e d to fiber). All DHP with LPS-F c o u l d be carried out safely. In exp. I: The s u p p r e s s i o n of tumor g r o w t h by DHP was s i g n i f i c a n t l y effective. In survival rate, t r e a t e d g r o u p 40%, N o n - t r e a t e d group 0%. In exp. 2: Tumor growth was further s u p p r e s s e d , and s u r v iv a l rate was 8/12 (6?%) in BCG priming group. In exp. 3: DHP s u p p r e s s e d the tumor g r o w t h s i g n i f i c a n t l y against the those of DHP(-) and sham DHP group. And s u r v i v a l day of DHP group also p r o l o n g e d s i g n i f i c a n t l y . In exp. 4: DHP with d e - a c y l a t e d LPS-F was not effective. E x t r a c o r p o r e a l c i r c u l a t i o n with LPS-F c o u l d be u t i l i z e d as an i m m u n o m o d u l a t o r or bioactivator.
66
IN I M M U N E M A N I P U L A T I O N
14:30 - 15:30
POSTER PRESENTATION
R o o m 1 (Naniwa Kaikan)
15:30 - 17:30
ORAL PRESENTATION
H a l l C (International House, Osaka)
Chairpersons: Anthony C. Allison (U.S.A.) Tomio Tada (Japan) * An asterisk indicates an oral presentation; the number following the asterisk is the order of the presentation.
WS18-1 -1 EXPERIMENTAL COMPARATIVE STUDY OF ADJUVANT AND NEOADJUVANT CHEMOTHERAPY, OR HORMONOTHERAPY OR IMMUNOTHERAPY APPLIED TO A HORMONE RECEPTOR CARRYING MURINE MAMMARY TUMOR. G. Math6, C. Bourut, E. Chenu, Y. Kldanl, Y. Mauvernay, A . V . $chally. ICIG, Hop. PauI-Brouase, 94804-VIIlelulf, France. MA 16/C Is a spontaneous, hormone-dependent, mouse mammary adenocarclnoma. It was Inlected s . c . on C 3 H / H e female mice on day O. Tumors were excised on day 16. Neoadluvant treatments were applied from day 1 to day 21 for hormonotherapy and Immunotherapy, and on days f , 6 end 9 for chemotherapy. Adluvant treatments were applied from day 21 to clay 42 for hormonotherapy and Immunotherapy, and on days 21, 26 end 29 for chemotherapy. Mixed (neoadluvant and edluvant) treatments combined the two patterns. Chemotherapy consisted of an oxalato-platlnum complex of trans-I-dach (I-OHP) at the dose of 6 m g / k g I . p . Hormonotherapy conalMed of D - T r p 6 - L H - R H at the dose of 1001¢g/kg I. p. . Immunotherapy consisted of zinc gluoonate, known to regulate CD8 cells at the dose of 6mg/kg per ca, and of bestafin, known to regulate CD4 cells at the dose of 8mg/kg per ca. In the condition where surgery alone did not cure any animal, adluvant or neoadluvant chemotherapy or the combination of both, induced about 30% cure at the second month, which Is a highly significant benefit I s compared to surgery alone. Adluvant hormonotherapy or neoadluvant or the combination of both, neoadtuvant and adluvant lmmunotherapy give a benefit which is not significantly different from that of chemotherapy.
WS18-2 *2 TRIAL OF A N T I C A N C E R I M M U N O - T H E R A P Y U S I N G H E M O P E R F U S I O N BY L I P O P O L Y S A C C H A R I D E I M M O B I L I Z E D FIBER K. Numa, T. Tani, Y. Endo, T. Yoshioka, M. Kodama. D e p a r t m e n t of Surgery, Shiga U n i v e r s i t y of Medical Science, Shiga Japan. L i p o p o l y s a c c h a r i d e (LPS) can be i m m o b i l i z e d to the insoluble carrier fiber (LPS-F) to utilize LPS as an a n t i c a n c e r agent without toxicity. The d e n s i t y of i m m o b i l i z e d LPS was 4 . 3 m g / g of p o l y s t y r e n e fiber. A n t i c a n c e r a c t i v i t i e s were e x a m i n e d in Vx2 tumor b e a r i n g rabbits by the t r e a t m e n t of direct h e m o p e r f u s i o n (DHP) with LPSF. Exp. I: Cancer b e a r i n g rabbits were t r e a t e d by single DHP with LPS-F 14 days after tumor inoculation. Exp. 2: A d d i n g BCG as a p r i m i n g agent. Exp. 3: U s i n g 0K-432 as a p r i m i n g agent. Exp. 4: T r e a t e d by DHP with dea cyl a t e d LPS-F (LPS was d e - a c y l a t e d by h y d r o x y l a m i n e and i m m o b i l i z e d to fiber). All DHP with LPS-F c o u l d be carried out safely. In exp. I: The s u p p r e s s i o n of tumor g r o w t h by DHP was s i g n i f i c a n t l y effective. In survival rate, t r e a t e d g r o u p 40%, N o n - t r e a t e d group 0%. In exp. 2: Tumor growth was further s u p p r e s s e d , and s u r v iv a l rate was 8/12 (6?%) in BCG priming group. In exp. 3: DHP s u p p r e s s e d the tumor g r o w t h s i g n i f i c a n t l y against the those of DHP(-) and sham DHP group. And s u r v i v a l day of DHP group also p r o l o n g e d s i g n i f i c a n t l y . In exp. 4: DHP with d e - a c y l a t e d LPS-F was not effective. E x t r a c o r p o r e a l c i r c u l a t i o n with LPS-F c o u l d be u t i l i z e d as an i m m u n o m o d u l a t o r or bioactivator.
66